Vericiguat safe drug for use in patients with coronary artery disease, finds research

• The systolic blood pressure decreased by 1.4-10 mmHg and diastolic blood pressure by 0.4-6 mmHg; both the changes were clinically insignificant.

• Heart rate increased by 1.8-7 bpm, which was also of clinical insignificance.

Adverse Events

• No serious adverse events were reported significantly with the use of vericiguat in comparison with the placebo (OR = 1.97; 95% CI = 0.39-9.91; p= 0.41).

• There was a greater overall adverse events rate between vericiguat and the placebo group (OR = 4.04; 95% CI = 2.17 - 7.52; p< 0.001).

Clinical Trials and Population

• Analysis involved all three randomized controlled trials with an enrollment of 151 patients.

• Therefore, minor adverse effects notwithstanding, vericiguat appears to still be safe in managing coronary artery disease.

This meta-analysis therefore shows that vericiguat is safe for the use of patients with coronary artery disease as it is free from a significant risk of serious adverse events. The minor adverse events were, however, more frequent in the vericiguat arm, and the clinical significance remains low. More clinical studies are required to confirm these results and make vericiguat a first-line therapy in cardiovascular practice.

Reference:

Bin Zarti, M., & Tamgheli, A. (2024). Safety of vericiguat in patients with coronary artery disease: A systematic review and meta-analysis. American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions.https://doi.org/10.1007/s40256-024-00701-0